Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
The Conversation logo

A new US study has added to the evidence that obesity is a risk factor for severe COVID-19. And in this paper, a particular finding has caught the media’s attention: the apparently greater risk posed by COVID-19 to men with obesity than women. But while it’s tempting to take this information at face value, there are several reasons not to.

There are lots of different ways to look at whether and how obesity increases the risk of COVID-19. Body mass index, or BMI, is the main measure used in studies investigating whether people with obesity have worse outcomes. You can easily calculate your BMI online if you know your weight and height.

The association between worse COVID-19 outcomes and obesity was recognised early on in the pandemic. The first large study investigating this relationship was released in July 2020 and used data from more than 17 million adults in England. It showed that having a BMI of over 40 – classified as “severe obesity” – almost doubled a person’s risk of dying from COVID-19. However, it didn’t provide data on people with BMIs in the lower “overweight” or “obese” ranges.

Read the full article on The Conversation website, written by Jamie Hartmann-Boyce (Nuffield Department of Primary Care Health Sciences).

Oxford is a subscribing member of The ConversationFind out how you can write for The Conversation.

Similar stories

First trimester placental scan - Artificial Intelligence in Health and Care Award

A first trimester 3D placental ultrasound scan which can predict fetal growth restriction and pre-eclampsia, could become part of a woman's routine care thanks to a new Artificial Intelligence in Health and Care Award.

Impaired antibody response to COVID-19 vaccination in patients with myeloid blood cancers

Oxford researchers have found that antibody responses to the first doses of COVID-19 vaccine in people with chronic myeloid blood cancers are not as strong as those among the general population.

Treating Needle Fears May Reduce COVID-19 Vaccine Hesitancy Rates by 10%

A new large-scale study shows that a quarter of the UK adult population screens positive for a potential injection phobia.

RECOVERY trial Regeneron’s monoclonal antibody combination reduces deaths for hospitalised COVID-19 patients

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial has demonstrated that the investigational antibody combination developed by Regeneron reduces the risk of death when given to patients hospitalised with severe COVID-19 who have not mounted a natural antibody response of their own.

Major new study could help protect millions of people with type 2 diabetes from cardiovascular disease

A new study led by the Nuffield Department of Population Health at the University of Oxford will research whether a daily tablet could help protect the millions of people worldwide with type 2 diabetes from developing cardiovascular disease.

Professor Susan Jebb appointed as Chair of the Food Standards Agency

Susan Jebb, Professor of Diet and Population Health in Oxford University’s Nuffield Department of Primary Care Health Sciences, has been appointed as the new Chair of the Food Standards Agency.